Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A

ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers f

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript

Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progr

Allogene Therapeutics said on Wednesday it has ended a key partnership for ​developing cell therapie

Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the an

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: A

Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, C

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the dev

SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) shares shot up 13.1% during mid-day tra

SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

U.S. stocks were mixed on Thursday, with the Dow Jones gaining 0.1%. Aehr Test Systems shares rose 1

Analysts change outlook on top names: Mizuho downgrades PYPL, B of A increases CIEN PT, Needham rais

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a

Jefferies analyst Roger Song maintains Allogene Therapeutics (NASDAQ:ALLO) with a Buy and raises

US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbir

Study Highlights Dagger Technology Showing that an Optimized CD70 CAR has the Potential to Protect A

SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling pote

Bernstein analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market P

Argus Research analyst William Pickering maintains Allogene Therapeutics (NASDAQ:ALLO) with a Mar

Citizens analyst Reni J. Benjamin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Market Out

US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnin

Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i

Baird analyst Jack Allen maintains Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and rai

HC Wainwright & Co. analyst Robert Burns maintains Allogene Therapeutics (NASDAQ:ALLO) with a

Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) was the target of some unusual options

Allogene Therapeutics, Inc. (NASDAQ:ALLO) today announced that it intends to offer and sell, in an u

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq:

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to d

U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt ro

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the de

IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the de

U.S. stock futures lower, Dow futures down 300 points. Worthington Steel Inc (NYSE: WS) shares fall